Geographic Atrophy: Insights Into Current Management and Potential Therapies

This activity is supported by an unrestricted educational grant from Apellis Pharmaceuticals.

Learning Objectives

Upon completion of this activity, the participant should be able to:

• Describe the prevalence of age-related macular degeneration (AMD) and classify by severity: early, intermediate, and advanced (ie, wet AMD and GA)
• Explain the pathogenesis of GA
• Distinguish which imaging modalities are best suited for GA evaluation
• Categorize new therapies in the pipeline for GA
• Evaluate the functional and anatomic outcomes used in managing patients with GA

Accreditation and Designation Statement

Provided by Evolve Medical Education

Accreditation Statement
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Evolve designates this enduring. material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Course Viewing Requirements
Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+

Faculty and Disclosures

Roger A. Goldberg, MD, MBA
Program Chair
Vitreoretinal Specialist
Bay Area Retina Associates
Walnut Creek, CA
Volunteer Faculty
California Pacific Medical Center Ophthalmology Residency
San Francisco, CA

Caroline R. Baumal, MD
Professor of Ophthalmology
New England Eye Center
Tufts University School of Medicine
Boston, MA

Aleksandra Rachitskaya, MD
Cole Eye Institute
Assistant Professor of Ophthalmology
Cleveland Clinic
Lerner College of Medicine
Cleveland, OH

SriniVas Sadda, MD
President and Chief Scientific Officer
Doheny Eye Institute
Professor of Ophthalmology
University of California – Los Angeles
Geffen School of Medicine
Los Angeles, CA

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Caroline R. Baumal, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Apellis, Carl Zeiss Meditech, Genentech, and Novartis.

Roger A. Goldberg, MD, MBA, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Carl Zeiss Meditec, Genentech, Novartis, and Regeneron Pharmaceuticals. Grant/Research Support: Aerie, Allergan, Apellis, Carl Zeiss Meditec, Chengdu Kanghong, Genentech, Graybug Vision, Neurotech, Novartis, Ribomic, and Santen. Speaker’s Bureau: Allergan and Genentech.

Aleksandra Rachitskaya, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Allergan, Carl Zeiss Meditec, Novartis, and Regeneron Pharmaceuticals. Grant/Research Support: Genentech and Novartis.

SriniVas R. Sadda, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Amgen, and Genentech/Roche. Grant/Research Support: Allergan, Carl Zeiss Meditec, CenterVue, Heidelberg Engineering, NGM Bio, Nidek, Novartis, Optos, Oxurion, Regeneron Pharmaceuticals, Topcon, and 4DMT. Speaker’s Bureau: Merck, Nidek, and Topcon. Other Financial Support: Carl Zeiss Meditec, CenterVue, Heidelberg Engineering, Nidek, Optos, and Topcon.

The Evolve staff and planners have no financial relationships with commercial interests. Scott Krzywonos, writer, and Nisha Mukherjee, MD, peer reviewer, have no financial relationships with
commercial interests.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Retina Today, or Apellis Pharmaceuticals.